2026-11-09

China A-share innovative-drug stocks rose intraday after choppy trading; Laimei Pharmaceutical jumped more than 15%, with Zhaoyan New Drug, Medicilon, Chengdu Xiandao, RemeGen and Nearshore Protein among the top gainers.

China A-share innovative-drug stocks rose intraday after choppy trading; Laimei Pharmaceutical jumped more than 15%, with Zhaoyan New Drug, Medicilon, Chengdu Xiandao, RemeGen and Nearshore Protein among the top gainers.

2026-11-09

A股创新药概念盘中震荡走高，莱美药业涨超15%，昭衍新药、美迪西、成都先导、荣昌生物、近岸蛋白涨幅靠前。

A股创新药概念盘中震荡走高，莱美药业涨超15%，昭衍新药、美迪西、成都先导、荣昌生物、近岸蛋白涨幅靠前。

2026-11-09

【期货热点追踪】生猪供强需弱未改、均重上升累库存，超跌修复遇上弱现实压制，生猪主力合约能否扭转下跌趋势？

【期货热点追踪】生猪供强需弱未改、均重上升累库存，超跌修复遇上弱现实压制，生猪主力合约能否扭转下跌趋势？

2026-11-09

Hong Kong biotech stocks were firmer in early trade. Zai Lab (09688.HK) jumped over 12%, Akeso (09926.HK) rose ~7%, Ascentage Pharma (06855.HK) gained ~5%, Kangnuoya (02162.HK) added ~4%, BeiGene (06160.HK) was up just over 3%, and Rongchang Bio (09995.HK) rose ~3%.

Hong Kong biotech stocks were firmer in early trade. Zai Lab (09688.HK) jumped over 12%, Akeso (09926.HK) rose ~7%, Ascentage Pharma (06855.HK) gained ~5%, Kangnuoya (02162.HK) added ~4%, BeiGene (06160.HK) was up just over 3%, and Rongchang Bio (09995.HK) rose ~3%.

2026-11-09

港股生物技术股盘初上扬，再鼎医药(09688.HK)大涨超12%，康方生物(09926.HK)涨近7%，亚盛医药(06855.HK)涨近5%，康诺亚(02162.HK)涨近4%，百济神州(06160.HK)涨超3%，荣昌生物(09995.HK)涨近3%。

港股生物技术股盘初上扬，再鼎医药(09688.HK)大涨超12%，康方生物(09926.HK)涨近7%，亚盛医药(06855.HK)涨近5%，康诺亚(02162.HK)涨近4%，百济神州(06160.HK)涨超3%，荣昌生物(09995.HK)涨近3%。

2026-11-09

President Trump endorsed a bipartisan bill to speed federal permitting for major energy and infrastructure projects ahead of a Senate procedural vote Monday, urging senators to support legislation he said would codify an "America First" energy agenda and accelerate pipelines, mines and power-plant construction. Supporters say the measure would shorten approvals critical to grid modernization, AI data-center builds and some clean-energy projects; it has backing from oil companies and renewable de

President Trump endorsed a bipartisan bill to speed federal permitting for major energy and infrastructure projects ahead of a Senate procedural vote Monday, urging senators to support legislation he said would codify an "America First" energy agenda and accelerate pipelines, mines and power-plant construction. Supporters say the measure would shorten approvals critical to grid modernization, AI data-center builds and some clean-energy projects; it has backing from oil companies and renewable developers. Passage faces obstacles: Congress has about two months left in the session, House Democratic leader Jeffries opposes the current text for lack of Democratic input, and progressive Democrats prefer to press for a stronger deal next year.